
# Assay-Ready Expanded (ARE) Human Hepatocytes




- Primary human hepatocytes that have been expanded in vitro
- Large batch sizes (up to 2000 vials) from the same donor for consistency from preliminary experiments to high-throughput screening
- Express CYP enzymes, are metabolically functional, polarized & can be infected by the Hepatitis C virus
- Ready-to-use directly in downstream applications




Hepatocyte morphology after 5 days in culture (40X)

### **CYP Metabolism Studies**

D	onor Inforn	nation		CYP Basal Activity (pmol/min/mg)				Fold Induction			
ID	Gender	Age	Race	CYP1A2	CYP2B6	CYP2C9	CYP3A4	CYP1A2	CYP2B6	CYP2C9	CYP3A4
Donor 1	F	48	С	$3.3 \pm 0.4$	40.3 ± 6.5	91.8 ± 5.5	21.4 ± 9.6	7.3	5.1	2.8	8.2
Donor 2	F	43	С	0.7 ± 1.4	71.1 ± 11.3	29.1 ± 21.4	77.8 ± 22.6	>5	24	1.4	2.3
Donor 3	М	0.25	Н	2.3 ± 0.1	33.6 ± 11.4	4.8 ± 3.1	42.9 ± 6.3	9.9	3.5	5.6	3.1
Donor 4	F	9	С	17.1 ± 0.5	68.4 ± 18.4	16.2 ± 0.9	178.3 ± 17	>5	1.8	0.6	6.5




Comparison of the Phase I CYP enzyme activity between ARE Hepatocytes, ARE Hepatocytes (CYP2D6 Overexpressing) & HepaRG cells (above). Inhibition of CYP enzymes by various compounds (below).



ax3701 ARE Hepatocytes
ax3702 ARE Hepatocytes,
CYP2D6 Overexpressing
ax3703 ARE Hepatocytes,
Genotoxicity Assay Validated


ax3720 ARE Liver Sinusoidal
Endothelial Cells
ax3721 ARE Liver Sinusoidal

**Epithelial Cell Culture Medium** 



Uptake of Low Density Lipoprotein (LDL) in ARE Liver Sinusoidal Endothelial Cells

## **Hepatotoxicity Studies**




### **Transporter Gene Expression**

# Primary Hepatocytes Axol ARE Hepatocytes HepG2 NTCP BSEP OCT1 MDR1 MRP3

Expression of hepatic transporter genes in primary hepatocytes, ARE Hepatocytes & HepG2 cells

# **Genotoxicity Studies**



Concentration (mg/ml)

Increasing cyclophosphamide concentration affects the percentage of cells with micronuclei (% MN) & cell viability